vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and HCI Group, Inc. (HCI). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($263.6M vs $246.2M, roughly 1.1× HCI Group, Inc.). HCI Group, Inc. runs the higher net margin — 39.7% vs 14.9%, a 24.8% gap on every dollar of revenue. On growth, HCI Group, Inc. posted the faster year-over-year revenue change (52.1% vs 9.8%). Over the past eight quarters, HCI Group, Inc.'s revenue compounded faster (9.2% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
BCPC vs HCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $246.2M |
| Net Profit | $39.2M | $97.7M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | 58.5% |
| Net Margin | 14.9% | 39.7% |
| Revenue YoY | 9.8% | 52.1% |
| Net Profit YoY | 16.8% | 3679.2% |
| EPS (diluted) | $1.21 | $7.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $246.2M | ||
| Q3 25 | $267.6M | $216.3M | ||
| Q2 25 | $255.5M | $221.9M | ||
| Q1 25 | $250.5M | $216.4M | ||
| Q4 24 | $240.0M | $161.9M | ||
| Q3 24 | $239.9M | $175.3M | ||
| Q2 24 | $234.1M | $206.2M | ||
| Q1 24 | $239.7M | $206.6M |
| Q4 25 | $39.2M | $97.7M | ||
| Q3 25 | $40.3M | $65.5M | ||
| Q2 25 | $38.3M | $66.2M | ||
| Q1 25 | $37.1M | $69.7M | ||
| Q4 24 | $33.6M | $2.6M | ||
| Q3 24 | $33.8M | $5.7M | ||
| Q2 24 | $32.1M | $54.1M | ||
| Q1 24 | $29.0M | $47.6M |
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 19.8% | 58.5% | ||
| Q3 25 | 20.4% | 41.9% | ||
| Q2 25 | 20.1% | 42.5% | ||
| Q1 25 | 20.4% | 46.4% | ||
| Q4 24 | 19.8% | 3.6% | ||
| Q3 24 | 20.0% | 8.0% | ||
| Q2 24 | 19.6% | 36.9% | ||
| Q1 24 | 17.4% | 37.5% |
| Q4 25 | 14.9% | 39.7% | ||
| Q3 25 | 15.1% | 30.3% | ||
| Q2 25 | 15.0% | 29.8% | ||
| Q1 25 | 14.8% | 32.2% | ||
| Q4 24 | 14.0% | 1.6% | ||
| Q3 24 | 14.1% | 3.2% | ||
| Q2 24 | 13.7% | 26.2% | ||
| Q1 24 | 12.1% | 23.0% |
| Q4 25 | $1.21 | $7.29 | ||
| Q3 25 | $1.24 | $4.90 | ||
| Q2 25 | $1.17 | $5.18 | ||
| Q1 25 | $1.13 | $5.35 | ||
| Q4 24 | $1.03 | $0.32 | ||
| Q3 24 | $1.03 | $0.52 | ||
| Q2 24 | $0.98 | $4.24 | ||
| Q1 24 | $0.89 | $3.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $1.2B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $1.0B |
| Total Assets | $1.7B | $2.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $1.2B | ||
| Q3 25 | $65.1M | $987.9M | ||
| Q2 25 | $65.4M | $947.2M | ||
| Q1 25 | $49.9M | $754.5M | ||
| Q4 24 | $49.5M | $532.5M | ||
| Q3 24 | $73.7M | $518.8M | ||
| Q2 24 | $63.7M | $445.8M | ||
| Q1 24 | $60.3M | $655.4M |
| Q4 25 | $1.3B | $1.0B | ||
| Q3 25 | $1.3B | $821.8M | ||
| Q2 25 | $1.3B | $758.6M | ||
| Q1 25 | $1.2B | $522.7M | ||
| Q4 24 | $1.1B | $453.3M | ||
| Q3 24 | $1.2B | $455.3M | ||
| Q2 24 | $1.1B | $447.3M | ||
| Q1 24 | $1.1B | $395.7M |
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | $2.3B | ||
| Q2 25 | $1.7B | $2.4B | ||
| Q1 25 | $1.6B | $2.3B | ||
| Q4 24 | $1.6B | $2.2B | ||
| Q3 24 | $1.6B | $2.0B | ||
| Q2 24 | $1.6B | $1.9B | ||
| Q1 24 | $1.6B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $444.4M |
| Free Cash FlowOCF − Capex | — | $440.8M |
| FCF MarginFCF / Revenue | — | 179.0% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | 1.72× | 4.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $771.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $444.4M | ||
| Q3 25 | $65.6M | $26.7M | ||
| Q2 25 | $47.3M | $145.0M | ||
| Q1 25 | $36.5M | $162.0M | ||
| Q4 24 | $52.3M | $331.8M | ||
| Q3 24 | $51.3M | $104.1M | ||
| Q2 24 | $45.0M | $-29.0M | ||
| Q1 24 | $33.4M | $182.0M |
| Q4 25 | — | $440.8M | ||
| Q3 25 | — | $25.9M | ||
| Q2 25 | — | $144.5M | ||
| Q1 25 | — | $160.3M | ||
| Q4 24 | — | $327.8M | ||
| Q3 24 | — | $103.2M | ||
| Q2 24 | — | $-30.1M | ||
| Q1 24 | — | $181.0M |
| Q4 25 | — | 179.0% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | 65.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 202.5% | ||
| Q3 24 | — | 58.9% | ||
| Q2 24 | — | -14.6% | ||
| Q1 24 | — | 87.6% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | 1.72× | 4.55× | ||
| Q3 25 | 1.63× | 0.41× | ||
| Q2 25 | 1.23× | 2.19× | ||
| Q1 25 | 0.98× | 2.32× | ||
| Q4 24 | 1.56× | 128.41× | ||
| Q3 24 | 1.52× | 18.33× | ||
| Q2 24 | 1.40× | -0.54× | ||
| Q1 24 | 1.15× | 3.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
